Symbols / GILD
GILD Chart
About
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 178.37B |
| Enterprise Value | 198.42B | Income | 8.51B | Sales | 29.44B |
| Book/sh | 18.29 | Cash/sh | 7.75 | Dividend Yield | 223.00% |
| Payout | 46.61% | Employees | — | IPO | — |
| P/E | 21.21 | Forward P/E | 14.88 | PEG | — |
| P/S | 6.06 | P/B | 7.86 | P/C | — |
| EV/EBITDA | 13.61 | EV/Sales | 6.74 | Quick Ratio | 1.23 |
| Current Ratio | 1.55 | Debt/Eq | 112.92 | LT Debt/Eq | — |
| EPS (ttm) | 6.78 | EPS next Y | 9.67 | EPS Growth | 23.30% |
| Revenue Growth | 4.70% | Earnings | 2026-04-23 | ROA | 12.52% |
| ROE | 40.66% | ROIC | — | Gross Margin | 78.84% |
| Oper. Margin | 37.38% | Profit Margin | 28.90% | Shs Outstand | 1.24B |
| Shs Float | 1.24B | Short Float | 1.91% | Short Ratio | 3.23 |
| Short Interest | — | 52W High | 157.29 | 52W Low | 93.37 |
| Beta | 0.39 | Avg Volume | 7.24M | Volume | 7.61M |
| Target Price | $156.59 | Recom | Buy | Prev Close | $147.12 |
| Price | $143.77 | Change | -2.28% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$156.59
Mean price target
2. Current target
$143.77
Latest analyst target
3. DCF / Fair value
$109.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$143.77
Low
$118.00
High
$177.00
Mean
$156.59
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | reit | Needham | Buy → Buy | $170 |
| 2026-02-20 | init | Barclays | — → Equal-Weight | $155 |
| 2026-02-11 | main | RBC Capital | Sector Perform → Sector Perform | $118 |
| 2026-02-11 | main | Truist Securities | Buy → Buy | $152 |
| 2026-02-11 | main | Wells Fargo | Overweight → Overweight | $165 |
| 2026-02-11 | main | Cantor Fitzgerald | Overweight → Overweight | $155 |
| 2026-02-11 | main | Scotiabank | Sector Outperform → Sector Outperform | $177 |
| 2026-02-11 | main | Needham | Buy → Buy | $170 |
| 2026-01-27 | main | Truist Securities | Buy → Buy | $145 |
| 2026-01-27 | main | Citigroup | Buy → Buy | $156 |
| 2026-01-26 | main | UBS | Buy → Buy | $155 |
| 2026-01-13 | main | Morgan Stanley | Overweight → Overweight | $150 |
| 2026-01-07 | main | Citigroup | Buy → Buy | $140 |
| 2025-12-12 | main | Morgan Stanley | Overweight → Overweight | $151 |
| 2025-12-10 | main | Wells Fargo | Overweight → Overweight | $150 |
| 2025-11-13 | main | Needham | Buy → Buy | $140 |
| 2025-11-13 | init | Scotiabank | — → Sector Outperform | $140 |
| 2025-11-03 | reit | Truist Securities | Buy → Buy | $145 |
| 2025-10-31 | main | Wells Fargo | Overweight → Overweight | $145 |
| 2025-10-31 | main | JP Morgan | Overweight → Overweight | $150 |
- Gilead Sciences Stock Surged 50%, Here's Why - Trefis Wed, 04 Feb 2026 08
- Gilead execs hit TD Cowen, Leerink, Barclays in March webcasts - Stock Titan Mon, 23 Feb 2026 21
- Mitsubishi UFJ Asset Management Co. Ltd. Has $287.48 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat hu, 26 Feb 2026 12
- Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings? - Yahoo Finance hu, 05 Feb 2026 08
- Top bank revisits gold stock price target for rest of 2026 - thestreet.com Sun, 22 Feb 2026 15
- Should You Buy Newmont Stock With Gold Prices Above $5,000? - The Motley Fool Mon, 23 Feb 2026 17
- Needham Reiterates Buy Rating for Gilead Sciences (GILD) with $1 - GuruFocus Mon, 23 Feb 2026 16
- Equinox Gold stock swings as dividend and buyback plans collide with softer gold prices - TechStock² ue, 24 Feb 2026 13
- Gilead Sciences: Buy This Stock For Both Dividend And Growth (NASDAQ:GILD) - Seeking Alpha ue, 10 Feb 2026 08
- Argus Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat Fri, 20 Feb 2026 15
- Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance Fri, 19 Dec 2025 08
- Between United Therapeutics and Gilead Sciences, Which Stock Looks Set to Break Out? - Trefis ue, 10 Feb 2026 06
- Barclays Initiates Coverage on GILD with Equal-Weight Rating | G - GuruFocus Sat, 21 Feb 2026 08
- Why Gilead Sciences (GILD) Outpaced the Stock Market Today - Yahoo Finance hu, 22 Jan 2026 08
- Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - MarketBeat hu, 12 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 25000 | 1666000.0 | — | Conversion of Exercise of derivative security at price 66.64 per share. | MERCIER JOHANNA | Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 28000 | 4324228.0 | — | Sale at price 154.18 - 155.62 per share. | MERCIER JOHANNA | Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 3000 | 463290.0 | — | Sale at price 154.43 per share. | DICKINSON ANDREW D | Chief Financial Officer | — | 2026-02-17 00:00:00 | D |
| 3 | 115640 | 7633396.0 | — | Conversion of Exercise of derivative security at price 66.01 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-02-05 00:00:00 | D |
| 4 | 115640 | 17346000.0 | — | Sale at price 150.00 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-02-05 00:00:00 | D |
| 5 | 44867 | — | — | Stock Award(Grant) at price 0.00 per share. | MERCIER JOHANNA | Officer | — | 2026-02-03 00:00:00 | D |
| 6 | 131675 | — | — | Stock Award(Grant) at price 0.00 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-02-03 00:00:00 | D |
| 7 | 44867 | — | — | Stock Award(Grant) at price 0.00 per share. | DICKINSON ANDREW D | Chief Financial Officer | — | 2026-02-03 00:00:00 | D |
| 8 | 10000 | 1398911.0 | — | Sale at price 139.54 - 140.24 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-01-28 00:00:00 | D |
| 9 | 115640 | 7633396.0 | — | Conversion of Exercise of derivative security at price 66.01 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-01-23 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -2.78B | -249.70M | -923.23M | -235.69M |
| TaxRateForCalcs | 0.30 | 0.18 | 0.21 | 0.25 |
| NormalizedEBITDA | 13.55B | 11.87B | 13.15B | 12.27B |
| TotalUnusualItems | -9.12B | -1.37B | -4.30B | -939.00M |
| TotalUnusualItemsExcludingGoodwill | -9.12B | -1.37B | -4.30B | -939.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 480.00M | 5.67B | 4.59B | 6.22B |
| ReconciledDepreciation | 2.77B | 2.69B | 2.10B | 2.05B |
| ReconciledCostOfRevenue | 6.25B | 6.50B | 5.66B | 6.60B |
| EBITDA | 4.43B | 10.50B | 8.85B | 11.33B |
| EBIT | 1.67B | 7.80B | 6.75B | 9.28B |
| NetInterestIncome | -696.00M | -568.00M | -829.00M | -1.00B |
| InterestExpense | 977.00M | 944.00M | 935.00M | 1.00B |
| InterestIncome | 281.00M | 376.00M | 106.00M | |
| NormalizedIncome | 6.82B | 6.79B | 7.97B | 6.93B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 480.00M | 5.67B | 4.59B | 6.22B |
| TotalExpenses | 18.25B | 18.31B | 16.31B | 16.45B |
| TotalOperatingIncomeAsReported | 1.66B | 7.61B | 7.33B | 9.92B |
| DilutedAverageShares | 1.25B | 1.26B | 1.26B | 1.26B |
| BasicAverageShares | 1.25B | 1.25B | 1.25B | 1.26B |
| DilutedEPS | 0.38 | 4.50 | 3.64 | 4.93 |
| BasicEPS | 0.38 | 4.54 | 3.66 | 4.96 |
| DilutedNIAvailtoComStockholders | 480.00M | 5.67B | 4.59B | 6.22B |
| NetIncomeCommonStockholders | 480.00M | 5.67B | 4.59B | 6.22B |
| NetIncome | 480.00M | 5.67B | 4.59B | 6.22B |
| MinorityInterests | 0.00 | 52.00M | 26.00M | 24.00M |
| NetIncomeIncludingNoncontrollingInterests | 480.00M | 5.61B | 4.57B | 6.20B |
| NetIncomeContinuousOperations | 479.00M | 5.61B | 4.57B | 6.20B |
| TaxProvision | 211.00M | 1.25B | 1.25B | 2.08B |
| PretaxIncome | 690.00M | 6.86B | 5.81B | 8.28B |
| OtherIncomeExpense | -9.12B | -1.38B | -4.33B | -1.58B |
| OtherNonOperatingIncomeExpenses | -2.00M | -11.00M | -29.00M | -639.00M |
| SpecialIncomeCharges | -8.84B | -1.21B | -3.64B | -939.00M |
| OtherSpecialCharges | 4.66B | 1.16B | 944.00M | 939.00M |
| WriteOff | 4.18B | 50.00M | 2.70B | 0.00 |
| GainOnSaleOfSecurity | -274.00M | -167.00M | -657.00M | |
| NetNonOperatingInterestIncomeExpense | -696.00M | -568.00M | -829.00M | -1.00B |
| InterestExpenseNonOperating | 977.00M | 944.00M | 935.00M | 1.00B |
| InterestIncomeNonOperating | 281.00M | 376.00M | 106.00M | |
| OperatingIncome | 10.51B | 8.81B | 10.97B | 10.86B |
| OperatingExpense | 12.00B | 11.81B | 10.65B | 9.85B |
| ResearchAndDevelopment | 5.91B | 5.72B | 4.98B | 4.60B |
| SellingGeneralAndAdministration | 6.09B | 6.09B | 5.67B | 5.25B |
| GrossProfit | 22.50B | 20.62B | 21.62B | 20.70B |
| CostOfRevenue | 6.25B | 6.50B | 5.66B | 6.60B |
| TotalRevenue | 28.75B | 27.12B | 27.28B | 27.30B |
| OperatingRevenue | 28.75B | 27.12B | 27.28B | 27.30B |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.25B | 1.25B | 1.25B | 1.25B |
| ShareIssued | 1.25B | 1.25B | 1.25B | 1.25B |
| NetDebt | 16.72B | 18.90B | 19.82B | 21.36B |
| TotalDebt | 26.71B | 24.99B | 25.23B | 26.70B |
| TangibleBookValue | -8.93B | -11.94B | -15.97B | -20.72B |
| InvestedCapital | 46.04B | 47.82B | 46.47B | 47.76B |
| WorkingCapital | 7.17B | 4.80B | 3.21B | 3.16B |
| NetTangibleAssets | -8.93B | -11.94B | -15.97B | -20.72B |
| CommonStockEquity | 19.33B | 22.83B | 21.24B | 21.07B |
| TotalCapitalization | 44.23B | 46.02B | 44.20B | 46.25B |
| TotalEquityGrossMinorityInterest | 19.25B | 22.75B | 21.21B | 21.06B |
| MinorityInterest | -84.00M | -84.00M | -31.00M | -5.00M |
| StockholdersEquity | 19.33B | 22.83B | 21.24B | 21.07B |
| GainsLossesNotAffectingRetainedEarnings | 132.00M | 28.00M | 2.00M | 83.00M |
| OtherEquityAdjustments | 132.00M | 28.00M | 2.00M | 83.00M |
| RetainedEarnings | 11.50B | 16.30B | 15.69B | 16.32B |
| AdditionalPaidInCapital | 7.70B | 6.50B | 5.55B | 4.66B |
| CapitalStock | 1.00M | 1.00M | 1.00M | 1.00M |
| CommonStock | 1.00M | 1.00M | 1.00M | 1.00M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 39.75B | 39.38B | 41.96B | 46.89B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 27.75B | 28.10B | 30.72B | 35.28B |
| OtherNonCurrentLiabilities | 1.29B | 1.28B | 1.18B | 976.00M |
| TradeandOtherPayablesNonCurrent | 830.00M | 2.04B | 3.92B | 4.77B |
| NonCurrentDeferredLiabilities | 724.00M | 1.59B | 2.67B | 4.36B |
| NonCurrentDeferredTaxesLiabilities | 724.00M | 1.59B | 2.67B | 4.36B |
| LongTermDebtAndCapitalLeaseObligation | 24.90B | 23.19B | 22.96B | 25.18B |
| LongTermDebt | 24.90B | 23.19B | 22.96B | 25.18B |
| CurrentLiabilities | 12.00B | 11.28B | 11.24B | 11.61B |
| OtherCurrentLiabilities | 2.27B | 2.33B | 2.18B | |
| CurrentDebtAndCapitalLeaseObligation | 1.81B | 1.80B | 2.27B | 1.52B |
| CurrentDebt | 1.81B | 1.80B | 2.27B | 1.52B |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.23B | 1.20B | 1.02B | 927.00M |
| CurrentProvisions | 321.00M | 387.00M | 422.00M | 499.00M |
| PayablesAndAccruedExpenses | 6.37B | 5.56B | 5.34B | 8.67B |
| CurrentAccruedExpenses | 3.89B | 3.80B | 3.48B | 7.42B |
| Payables | 2.48B | 1.76B | 1.86B | 1.24B |
| TotalTaxPayable | 1.65B | 1.21B | 959.00M | 539.00M |
| IncomeTaxPayable | 1.65B | 1.21B | 959.00M | 539.00M |
| AccountsPayable | 833.00M | 550.00M | 905.00M | 705.00M |
| TotalAssets | 58.99B | 62.12B | 63.17B | 67.95B |
| TotalNonCurrentAssets | 39.82B | 46.04B | 48.73B | 53.18B |
| OtherNonCurrentAssets | 6.15B | 4.79B | 4.80B | 4.96B |
| InvestmentsAndAdvances | 0.00 | 1.16B | 1.25B | 1.31B |
| InvestmentinFinancialAssets | 0.00 | 1.16B | 1.25B | 1.31B |
| AvailableForSaleSecurities | 1.16B | 1.25B | 1.31B | |
| GoodwillAndOtherIntangibleAssets | 28.26B | 34.77B | 37.21B | 41.79B |
| OtherIntangibleAssets | 19.95B | 26.45B | 28.89B | 33.45B |
| Goodwill | 8.31B | 8.31B | 8.31B | 8.33B |
| NetPPE | 5.41B | 5.32B | 5.47B | 5.12B |
| AccumulatedDepreciation | -2.47B | -2.45B | -2.19B | -1.89B |
| GrossPPE | 7.88B | 7.77B | 7.66B | 7.01B |
| ConstructionInProgress | 501.00M | 661.00M | 719.00M | 1.06B |
| OtherProperties | 1.19B | 1.15B | 1.11B | 952.00M |
| MachineryFurnitureEquipment | 1.09B | 1.07B | 880.00M | 807.00M |
| BuildingsAndImprovements | 4.54B | 4.33B | 4.39B | 3.79B |
| LandAndImprovements | 561.00M | 561.00M | 562.00M | 404.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 19.17B | 16.09B | 14.44B | 14.77B |
| OtherCurrentAssets | 995.00M | 2.37B | 1.77B | 2.14B |
| PrepaidAssets | 480.00M | 1.77B | 2.14B | |
| Inventory | 1.71B | 1.79B | 1.51B | 1.62B |
| Receivables | 4.42B | 4.66B | 4.78B | 4.49B |
| AccountsReceivable | 4.42B | 4.66B | 4.78B | 4.49B |
| AllowanceForDoubtfulAccountsReceivable | -900.00M | -836.00M | -687.00M | -785.00M |
| GrossAccountsReceivable | 5.32B | 5.50B | 5.46B | 5.28B |
| CashCashEquivalentsAndShortTermInvestments | 11.57B | 7.26B | 6.38B | 6.52B |
| OtherShortTermInvestments | 1.58B | 1.18B | 973.00M | 1.18B |
| CashAndCashEquivalents | 9.99B | 6.08B | 5.41B | 5.34B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 10.30B | 7.42B | 8.34B | 10.80B |
| RepurchaseOfCapitalStock | -1.15B | -1.00B | -1.40B | -546.00M |
| RepaymentOfDebt | -1.97B | -2.25B | -1.50B | -4.75B |
| IssuanceOfDebt | 3.46B | 1.98B | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 422.00M | 232.00M | 309.00M | 169.00M |
| CapitalExpenditure | -523.00M | -585.00M | -728.00M | -579.00M |
| InterestPaidSupplementalData | 951.00M | 891.00M | 907.00M | 979.00M |
| IncomeTaxPaidSupplementalData | 2.78B | 3.99B | 3.14B | 2.51B |
| EndCashPosition | 9.99B | 6.08B | 5.41B | 5.34B |
| BeginningCashPosition | 6.08B | 5.41B | 5.34B | 6.00B |
| EffectOfExchangeRateChanges | -40.00M | 57.00M | -63.00M | -35.00M |
| ChangesInCash | 3.95B | 616.00M | 137.00M | -624.00M |
| FinancingCashFlow | -3.43B | -5.12B | -6.47B | -8.88B |
| CashFlowFromContinuingFinancingActivities | -3.43B | -5.13B | -6.47B | -8.88B |
| NetOtherFinancingCharges | -281.00M | -278.00M | -173.00M | -145.00M |
| CashDividendsPaid | -3.92B | -3.81B | -3.71B | -3.60B |
| CommonStockDividendPaid | -3.92B | -3.81B | -3.71B | -3.60B |
| NetCommonStockIssuance | -728.00M | -768.00M | -1.09B | -377.00M |
| CommonStockPayments | -1.15B | -1.00B | -1.40B | -546.00M |
| CommonStockIssuance | 422.00M | 232.00M | 309.00M | 169.00M |
| NetIssuancePaymentsOfDebt | 1.49B | -270.00M | -1.50B | -4.75B |
| NetLongTermDebtIssuance | 1.49B | -270.00M | -1.50B | -4.75B |
| LongTermDebtPayments | -1.97B | -2.25B | -1.50B | -4.75B |
| LongTermDebtIssuance | 3.46B | 1.98B | 0.00 | 0.00 |
| InvestingCashFlow | -3.45B | -2.27B | -2.47B | -3.13B |
| CashFlowFromContinuingInvestingActivities | -3.45B | -2.27B | -2.47B | -3.13B |
| NetOtherInvestingChanges | 58.00M | -1.00M | 19.00M | |
| NetInvestmentPurchaseAndSale | 1.86B | -528.00M | 60.00M | -987.00M |
| SaleOfInvestment | 2.59B | 1.84B | 2.00B | 2.91B |
| PurchaseOfInvestment | -736.00M | -2.37B | -1.94B | -3.90B |
| NetBusinessPurchaseAndSale | -4.84B | -1.15B | -1.80B | -1.58B |
| PurchaseOfBusiness | -4.84B | -1.15B | -1.80B | -1.58B |
| CapitalExpenditureReported | -523.00M | -585.00M | -728.00M | -579.00M |
| OperatingCashFlow | 10.83B | 8.01B | 9.07B | 11.38B |
| CashFlowFromContinuingOperatingActivities | 10.83B | 8.01B | 9.07B | 11.38B |
| ChangeInWorkingCapital | -880.00M | -2.30B | -1.76B | 489.00M |
| ChangeInOtherWorkingCapital | -732.00M | -1.77B | -364.00M | -361.00M |
| ChangeInPayablesAndAccruedExpense | 398.00M | 111.00M | -549.00M | 571.00M |
| ChangeInAccruedExpense | 108.00M | 458.00M | -775.00M | 689.00M |
| ChangeInPayable | 290.00M | -347.00M | 226.00M | -118.00M |
| ChangeInAccountPayable | 290.00M | -347.00M | 226.00M | -118.00M |
| ChangeInTaxPayable | -568.00M | -364.00M | ||
| ChangeInIncomeTaxPayable | -568.00M | -364.00M | ||
| ChangeInPrepaidAssets | -259.00M | 39.00M | -134.00M | -45.00M |
| ChangeInInventory | -426.00M | -842.00M | -310.00M | 11.00M |
| ChangeInReceivables | 139.00M | 157.00M | -406.00M | 313.00M |
| ChangesInAccountReceivables | 139.00M | 157.00M | -406.00M | 313.00M |
| OtherNonCashItems | 5.02B | 1.98B | 1.72B | 1.51B |
| StockBasedCompensation | 835.00M | 766.00M | 637.00M | 635.00M |
| AssetImpairmentCharge | 4.18B | 50.00M | 2.70B | 0.00 |
| DeferredTax | -1.84B | -962.00M | -1.55B | -116.00M |
| DeferredIncomeTax | -1.84B | -962.00M | -1.55B | -116.00M |
| DepreciationAmortizationDepletion | 2.77B | 2.69B | 2.10B | 2.05B |
| DepreciationAndAmortization | 2.77B | 2.69B | 2.10B | 2.05B |
| AmortizationCashFlow | 2.39B | 2.34B | 1.78B | 1.72B |
| AmortizationOfIntangibles | 2.39B | 2.34B | 1.78B | 1.72B |
| Depreciation | 381.00M | 354.00M | 323.00M | 329.00M |
| OperatingGainsLosses | 274.00M | 167.00M | 657.00M | 610.00M |
| GainLossOnInvestmentSecurities | 274.00M | 167.00M | 657.00M | 610.00M |
| NetIncomeFromContinuingOperations | 480.00M | 5.61B | 4.57B | 6.20B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GILD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|